Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

Overview of attention for article published in Journal of Clinical Oncology, May 2015

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news: 44 news outlets
blogs: 16 blogs
policy: 1 policy source
twitter: 98 X users
patent: 93 patents
facebook: 13 Facebook pages

wikipedia: 10 Wikipedia pages
googleplus: 4 Google+ users
reddit: 8 Redditors
f1000: 1 research highlight platform
guideline: 8 clinical guideline sources
podcasts: 1 podcast

Readers on

mendeley: 1571 Mendeley
citeulike: 1 CiteULike

So far, Altmetric has seen 14 public wall posts from 13 users.

Банк шкіри. Лікування опіків, 25 Jan 2016

Небезпечний вірус зможе врятувати людей від раку шкіри! Вакцина проти раку шкіри (меланоми), вироблена на основі вірусу герпесу…

Help Save Darcy, 26 Nov 2015

#TVEC (#Talimogene #Laherparepvec) is 1st #oncolytic #immunotherapy for #melanoma in Phase III #clinicaltrial w therapeutic…

The Medical Educator Consortium, 22 Nov 2015

Presented in part at the 49th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 31-June 4, 2013…

American Society of Clinical Oncology, 22 Nov 2015

Phase III melanoma trial results published in our Journal of Clinical Oncology

This page shows the most recent Facebook posts that mention this research output. Click here to find out how to access more activity, including 10 additional Facebook posts.